Abstract
Ethiopia is the second most populous country in Africa and the sixth most affected by COVID-19 on the continent. Despite having experienced five infection waves, >499 000 cases, and ∼7 500 COVID-19-related deaths as of January 2023, there is still no detailed genomic epidemiological report on the introduction and spread of SARS-CoV-2 in Ethiopia. In this study, we reconstructed and elucidated the COVID-19 epidemic dynamics. Specifically, we investigated the introduction, local transmission, ongoing evolution, and spread of SARS-CoV-2 during the first four infection waves using 353 high-quality near-whole genomes sampled in Ethiopia. Our results show that whereas viral introductions seeded the first wave, subsequent waves were seeded by local transmission. The B.1.480 lineage emerged in the first wave and notably remained in circulation even after the emergence of the Alpha variant. The B.1.480 was out-competed by the Delta variant. Notably, Ethiopia’s lack of local sequencing capacity was further limited by sporadic, uneven, and insufficient sampling that limited the incorporation of genomic epidemiology in the epidemic public health response in Ethiopia. These results highlight Ethiopia’s role in SARS-CoV-2 dissemination and the urgent need for balanced, near-real-time genomic sequencing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was financed by Addis Ababa University through the COVID-19-AAU research fund for staff with a reference #- PR/5.15/590/12/20 and adaptive research and problem-solving projects with Ref # AR/043/2021 and RD/PY-148/2021. Also, this work was realized by the generous financial and technical support of the AU through Africa CDC, PGI. No more external funding was received. The APC was funded by Africa Pathogen Genomics Initiative (Africa PGI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and got approved by Addis Ababa University, College of Health Science Institutional Review Board (IRB) (IRB # 029/20/Lab), IRB of the Department of Medical Laboratory Sciences, Addis Ababa University (reference #-MLS/174/21), IRB office of Addis Ababa City Administration Health Bureau, AAPHREML (Reference #- AAHB/4039/227) and also from Addis Ababa University, College of Natural and Computational Science IRB (IRB #- CNCSDO/604/13/2021), by Yekatit 12 Hospital Medical College (IRB protocol # 75/20) and also reviewed and approved by the Federal Democratic Republic of Ethiopia National Ethics Committee at the Ministry of Science and Higher Education (MoSHE) (IRB #021/246/820/21).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the generated sequences used for this manuscript have been deposited in the GISAID sequence database and are purely publicly available. However its subject to the terms and conditions of the GISAID database https://www.gisaid.org/GISAID Identifier: EPI_SET_221214bg DOI: 10.55876/gis8.221214bg.
Acronyms /abbreviations
- AAPHREML
- Addis Ababa public health research and emergency management laboratory
- AAU
- Addis Ababa University
- ACDC
- Africa center for disease prevention and control
- CERI
- Centre for Epidemic Response and Innovation
- CI
- Confidence Interval
- CT
- Cycle Threshold
- GISAID
- Global Initiative on Sharing All Influenza Data
- KRISP
- KwaZulu-Natal Research Innovation and Sequencing Platform
- NAAT
- Nucleic Acid Amplification Tests
- PCR
- Polymerase Chain Reaction
- RNA
- Ribose Nucleic Acid
- RT-PCR
- Reverse Transcriptase Polymerase Chain Reaction S
- ARS-CoV-2
- severe acute respiratory syndrome novel corona virus-2
- VOCs
- Variants of Concern
- VTM
- Virus Transport Medium
- WHO
- World Health Organization
- SDG
- sustainable development goal
- COVID-19
- Coronavirus disease 2019
